- Home
- MPB vs VERV Comparison
MPB vs VERV Comparison
Compare MPB & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- VERV
- Stock Information
- Founded
- MPB 1868
- VERV 2018
- Country
- MPB United States
- VERV United States
- Employees
- MPB N/A
- VERV N/A
- Industry
- MPB Major Banks
- VERV Medicinal Chemicals and Botanical Products
- Sector
- MPB Finance
- VERV Health Care
- Exchange
- MPB Nasdaq
- VERV Nasdaq
- Market Cap
- MPB 467.7M
- VERV 384.2M
- IPO Year
- MPB N/A
- VERV 2021
- Fundamental
- Price
- MPB $26.65
- VERV $4.45
- Analyst Decision
- MPB Buy
- VERV Strong Buy
- Analyst Count
- MPB 2
- VERV 6
- Target Price
- MPB $36.00
- VERV $25.75
- AVG Volume (30 Days)
- MPB 86.0K
- VERV 2.9M
- Earning Date
- MPB 07-23-2025
- VERV 05-14-2025
- Dividend Yield
- MPB 3.00%
- VERV N/A
- EPS Growth
- MPB 23.94
- VERV N/A
- EPS
- MPB 2.88
- VERV N/A
- Revenue
- MPB $181,865,000.00
- VERV $59,613,000.00
- Revenue This Year
- MPB $24.31
- VERV $6.18
- Revenue Next Year
- MPB $13.74
- VERV N/A
- P/E Ratio
- MPB $9.26
- VERV N/A
- Revenue Growth
- MPB 9.21
- VERV 271.44
- 52 Week Low
- MPB $20.03
- VERV $2.87
- 52 Week High
- MPB $33.87
- VERV $9.31
- Technical
- Relative Strength Index (RSI)
- MPB 41.02
- VERV 47.78
- Support Level
- MPB $26.18
- VERV $3.89
- Resistance Level
- MPB $27.60
- VERV $4.63
- Average True Range (ATR)
- MPB 0.53
- VERV 0.41
- MACD
- MPB -0.27
- VERV 0.02
- Stochastic Oscillator
- MPB 15.31
- VERV 47.06
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.